REGENXBIO Inc. (RGNX) Balance Sheet

The consistent erosion of equity across every quarter in the series — with no offsetting capital raises or retained earnings generation large enough to reverse the trend — suggests the balance sheet is absorbing losses faster than any financing event or revenue inflection can replenish it. Total assets have simultaneously declined from $629.2M to $386.6M, indicating the company is shrinking in scale rather than deploying capital toward growth, which may limit strategic flexibility going forward. Investors should consider whether this trajectory reflects a deliberate asset-light transition or simply the arithmetic of sustained burn against a shrinking capital base.

The equity decline is almost entirely attributable to accumulated losses rather than share repurchases or dividend distributions, as the company paid no dividends and repurchased only $0.3M of stock across the full period, meaning shareholders' book value is being consumed by operations and milestone-related costs rather than returned through capital allocation. With equity now at $71.8M against $314.9M in total liabilities, the equity cushion is thin enough that any further loss accumulation or restructuring charge could push the company toward a negative equity position — an event that would materially alter its financing options.

Although the current ratio of 2.86 and quick ratio implications suggest no immediate insolvency risk, the cash position of $36.5M appears thin relative to the observed quarterly operating cash burn of approximately $60–63M, which would imply a runway of only one to two quarters if burn rates persist without milestone-driven revenue recognition. The deferred revenue balance of $25.3M may provide some counterbalance, but it represents contracted obligations rather than freely deployable liquidity. The sharp cash dip to $15.2M in 2026Q1 followed by a partial recovery to $36.5M in 2026Q2 suggests the liquidity position is highly sensitive to milestone timing, making the company's ability to maintain operations dependent on external financing or further milestone receipts.

The sharp debt build in mid-2025, followed by a rapid $200M reduction by early 2026, suggests the company drew on external financing during a period of acute cash pressure and subsequently repaid or restructured that debt — potentially after milestone receipts or asset monetization. The current D/E of 0.96 remains elevated relative to the sub-0.50 levels seen through 2024, and with equity at only $71.8M, even moderate debt carrying costs could compound the pressure on book value. The absence of goodwill on the balance sheet means there is no acquired-asset cushion to absorb future losses, leaving debt repayment capacity entirely dependent on operating cash generation that has been negative in nearly every quarter observed.